Innovent Starts US Trial of “Pivotal” CD47 Immunotherapy

Innovent Starts US Trial of “Pivotal” CD47 Immunotherapy

Innovent Biologics of Suzhou has begun a US Phase I trial of its anti-CD47 mAb candidate (IBI188) in patients with advanced malignant tumors. By binding to the CD47 antigen on tumor cells, IBI188 is expected to block the CD47-SIRPα signaling...

Read more
Abbisko Completes $42 Million Series B Funding for Oncology Candidates

Abbisko Completes $42 Million Series B Funding for Oncology Candidates

Abbisko Therapeutics of Shanghai completed a $42 million series B fundraising led by new investor Qiming, which it will use to start clinical trials of its oncology molecules and expand its discovery pipeline. Later this year, the company expects...

Read more
The “Cambrian Explosion” of Innovative Drugs in China Biopharma: Five Themes

The “Cambrian Explosion” of Innovative Drugs in China Biopharma: Five Themes

China is currently in the middle of a “Cambrian Explosion” of new drugs, according to Franck Le Deu, Senior Partner and Head of Greater China Healthcare practice at McKinsey & Company. The Cambrian Explosion is the period in...

Read more
Celgene Pays Exscientia $25 Million up Front for 3-Year AI Research Deal

Celgene Pays Exscientia $25 Million up Front for 3-Year AI Research Deal

UK-based Exscientia signed a three-year artificial intelligence (AI)-based drug discovery collaboration with Celgene. As part of the deal, Celgene is paying Exscientia $25 million upfront as well as various undisclosed milestone payments...

Read more
WuXi STA forms Strategic Partnership with Beta Pharma

WuXi STA forms Strategic Partnership with Beta Pharma

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Beta Pharma, a biotech company focusing on innovative drug discovery and development in oncology, announce a strategic partnership. Under the terms of the collaboration...

Read more
Xiangxue Approved to Start China Trial of T-Cell Therapy for Solid Tumors

Xiangxue Approved to Start China Trial of T-Cell Therapy for Solid Tumors

Guangzhou Xiangxue Life Sciences (XLifeSc), a subsidiary of Xiangxue Pharmaceutical, was approved by China’s NMPA to start clinical studies of its T-cell receptor Affinity Enhanced Specific T-cell (TAEST) therapy in patients with solid...

Read more
WuXi Biologics Receives EMA GMP Certificates

WuXi Biologics Receives EMA GMP Certificates

Wuxi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received EMA GMP...

Read more
Cellular Biomedicine Group Announces Proposed Follow-on Offering of Common Stock

Cellular Biomedicine Group Announces Proposed Follow-on Offering of Common Stock

Cellular Biomedicine Group Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical company engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it intends to...

Read more
BGI’s GenoImmune Raises $18 Million for Neoantigen Discovery Services

BGI’s GenoImmune Raises $18 Million for Neoantigen Discovery Services

GenoImmune, a subsidiary of Shenzhen sequencing company BGI, raised $18 million in an A funding round to support its neoantigen discovery for new immunotherapy candidates. The company has developed a service package to detect neoantigens by...

Read more
Tianjin’s CanSino to Raise $160.5 Million for Novel Vaccines in Hong Kong IPO

Tianjin’s CanSino to Raise $160.5 Million for Novel Vaccines in Hong Kong IPO

Tianjin CanSino Biologics, a vaccine company, expects to raise up to $160.5 million in a Hong Kong IPO, which will begin trading on March 28. The company is developing 15 vaccine candidates for 12 disease areas. Its Ebola vaccine has been...

Read more
Canada to create national drug agency to help cut cost of medicines

Canada to create national drug agency to help cut cost of medicines

Canada will create a national drug agency to help cut the cost of prescription medications as part of a plan to broaden the state-funded healthcare program, the finance ministry said in its budget on Tuesday. Unlike other countries with universal...

Read more
I-Mab Biopharma Announces Dosing of First Subject in Phase 1 Clinical Trial of Anti-GM-CSF Monoclonal Antibody TJM2 in the United States

I-Mab Biopharma Announces Dosing of First Subject in Phase 1 Clinical Trial of Anti-GM-CSF Monoclonal Antibody TJM2 in the United States

I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, today announced dosing of the first healthy subject in a...

Read more
Do NOT follow this link or you will be banned from the site!